Share on LinkedInShare on LinkedIn

ARTICLE · 26 AUGUST 2022

Market Intelligence Thought Leadership Award Winner

PMPRB Interim Guidance Updated

On August 18, 2022, PMPRB announced its Decision resulting from the consultation on the PMPRB Price Review Approach During the Interim Period following publication of Amendments to the Patented Medicines Regulation...

CanadaFood, Drugs, Healthcare, Life Sciences

On August 18, 2022, PMPRB announced its Decision resulting from the consultation on the PMPRB Price Review Approach During the Interim Period following publication of Amendments to the Patented Medicines Regulations – Canada.ca

The 'Interim Period' is from July 1, 2022 until a final set of price regulatory guidelines is published (expected for end of 2022).

In short, the Board has decided to proceed with the interim guidance as initially proposed in the June 30, 2022 Notice and Comment, with two important clarifications. That guidance is summarized below, with the clarifications underlined:

1. Existing Medicines

During the Interim Period, the price of a patented medicine will not trigger an investigation if:

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from